Glenmark Pharmaceuticals USA launches Epinephrine Injection USP
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The Alathur facility specializes in the production of Cephalosporin antibiotics
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Offers affordable, high-quality solutions for diabetes care
Subscribe To Our Newsletter & Stay Updated